History and clinical implications of PAPP-A2 in human growth: When reflecting on idiopathic short stature leads to a specific and new diagnosis: Understanding the concept of “low IGF-I availability”

Jesús Argente, Luis A. Pérez-Jurado

Research output: Contribution to journalLetterpeer-review

6 Citations (Scopus)


As a result of our publication of the first patients with short stature due to a mutation in the gene for PAPP-A2 the question, “Why did you continue to study these patients when they were not more than 2 SDS below normal?” has been proposed surprisingly frequently. We would like to communicate our opinions on why these patients were studied and share the experience on how this process took place. In addition, the choice of treatment is also discussed. We believe that this discovery process is a good example of good clinical practice and international collaboration.

Original languageEnglish
Pages (from-to)17-19
Number of pages3
JournalGrowth Hormone and IGF Research
Publication statusPublished or Issued - Jun 2018


  • ALS
  • GH
  • IGF-I
  • PAPP-A
  • PAPP-A2
  • Short stature

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this